ReviewPharmacological reports : PR2026
Non-invasive pharmacological advances in early retinopathy treatment: bioactive herbal compounds, polymer delivery systems, and computational bioprospecting of functional targets.
Review in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between endothelin-1 and diabetic retinopathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Formulation development and preclinical assessment of ethyl acetate fraction of Saraca asoca (EASA) flowers for cataract management.International ophthalmology · 2026Article
- Beneficial Effects of Natural Bioactive Compounds on Eye Health: A Narrative Review.International journal of molecular sciences · 2026Review
- Efficacy and Safety of Chinese Medicine Eye Nebulization in the Treatment of Diabetic Retinopathy: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Comparative Evaluation of Glycaemic and Non-Glycaemic Factors as Determinants of Retinopathy Status in an Adult Population: A Case-Control Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-vascular endothelial growth factor (anti-VEGF), laser, and vitrectomy therapy are commonly used for the management of vision-threatening posterior eye disease (PED), but non-invasive alternatives have garnered increasing popularity as proactive preventative strategies for early retinopathy, such as targeted plant-based diets or herbal supplements. However, only some plants contain bioactive compounds that specifically target retinal degeneration and demonstrate potent pharmacological benefits that are cost-effective, safe, and accessible for at-risk individuals. This review pinpoints plant bioactive compounds, specifically polyphenols and carotenoids, that target retinopathy, with a focus on apoptotic, angiogenesis, inflammation, and oxidative pathways leading to visible, functional, and vascular macula improvements. Innovations accelerating therapeutic applications of these botanicals for ocular delivery were then explored. Finally, advancements in disease assessments and the computational methods for early retinopathy biomarker diagnosis and treatment, particularly designed to bio-prospect plant-based therapies, were also reviewed to guide future developments and address translational limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.